Minoxidil and PP405 Interaction: Compatible | Peptide Database

FDA-approved for reduction of elevated total cholesterol and LDL-C in patients with primary hyperlipidemia, either as monotherapy or in combination with a statin. Reduces LDL by approximately 18% as monotherapy and provides an additional 25% reduction when added to ongoing statin therapy. Widely used off-label by anabolic steroid users to counteract the significant lipid disturbances caused by AAS, particularly oral 17-alpha-alkylated steroids. Oral compounds like oxandrolone can reduce HDL by 50% or more and elevate LDL substantially. Ezetimibe helps blunt LDL elevation while its non-hepatotoxic profile makes it preferable to statins during cycles involving liver-stressing orals. When LDL targets are not achieved with statin monotherapy, adding ezetimibe provides a complementary mechanism of action. The IMPROVE-IT trial demonstrated that the combination of ezetimibe plus simvastatin reduced cardiovascular events compared to simvastatin alone in post-acute coronary syndrome patients. The IMPROVE-IT trial established that adding ezetimibe to simvastatin therapy reduced the composite endpoint of cardiovascular death, major coronary events, and stroke by 6.4% over 7 years in patients with recent acute coronary syndrome. This was the first trial to demonstrate that a non-statin LDL-lowering agent provides incremental cardiovascular benefit. Approved as adjunctive therapy for homozygous familial hypercholesterolemia (HoFH) in combination with statins. Also used in heterozygous FH when statin monotherapy is insufficient to reach LDL targets. Particularly useful in patients who cannot tolerate high-dose statins.

FDA-approved (as Renova 0.05%) for the mitigation of fine facial wrinkles caused by chronic sun exposure. Clinical trials demonstrate measurable improvement in fine lines, tactile roughness, and mottled hyperpigmentation with 24-48 weeks of use. Accelerates turnover of melanin-laden keratinocytes, reducing the appearance of sunspots, melasma, and post-inflammatory hyperpigmentation. Often combined with hydroquinone and a corticosteroid in the classic Kligman formula. Improves tactile smoothness and skin surface regularity by normalizing the keratinization process and promoting orderly epidermal differentiation. Stimulates new collagen deposition in the papillary dermis, partially reversing the collagen degradation caused by UV-induced photoaging. Measurable increases in procollagen I have been documented histologically. First-line topical retinoid for non-inflammatory acne. Normalizes follicular keratinization, preventing the formation of microcomedones that are the precursor to all acne lesions. Effective as monotherapy for mild inflammatory acne and as combination therapy with benzoyl peroxide or topical antibiotics for moderate acne. Reduces both comedonal and papulopustular lesions. Recommended as long-term maintenance to prevent acne relapse after initial clearance. Low-concentration formulations (0.025%) are well-tolerated for indefinite maintenance use.